Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03924895
Title Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

invasive bladder transitional cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.